Phase 2 N=27 A Phase 1/2 Study to Evaluate MEDI4736
Advanced Solid Tumors
Primary: Number of Participants With Dose-limiting Toxicities in the Dose-escalation Phase — 0; 0; 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=121 Aromatase Inhibitor Host Factors Study
Breast Neoplasms
Primary: Part A Correlation of Day 29 Estradiol With BMI — 0.06 correlation coefficient
N/A N=36 Clinical Performance Assessment of a Daily Wear Monthly Replacement Soft Silicone Hydrogel Contact Lens
Refractive Errors
Primary: Distance VA (logMAR) With Study Lenses — -0.13; -0.14 logMAR
Phase 2 N=19 Intranasal Insulin and Post-stroke Cognition: A Pilot Study
Stroke
Primary: Composite of Memory t Scores — 39.5; 39.7 score on a scale
Phase 1 N=5 Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors
Solid Tumors
Primary: Number of Participants With Dose Limiting Toxicities — 0; 1; 0; 0 Participants
N/A N=86 Clinical Performance of a Monthly Replacement Silicone Hydrogel Lens
Refractive Errors
Primary: Distance Visual Acuity (VA) — -0.09; -0.09 logMAR
Phase 2 N=218 First Line Chemotherapy Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer
Primary: Time to Disease Progression — 4.6; 6.0; 4.1 months — p=0.40
Phase 2 N=40 Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation
COVID 19 · SARS-CoV 2 · Pneumonia
Primary: Subjects Alive and Off of Oxygen at Day 14 — 12; 9 Participants
N/A N=118 Clinical Evaluation of a Daily Wear Monthly Replacement Silicone Hydrogel Lens
Refractive Errors
Primary: Distance VA (logMAR) With Study Lenses - Completed Eyes — -0.07; -0.07; -0.08; -0.07 logMAR
Phase 3 N=13 Cardiovascular Effects of Racemic Epinephrine Pellets
Epinephrine Causing Adverse Effects in Therapeutic Use
Primary: Cardiovascular Outcomes — 91.5; 93.4 Beats Per Minute
Phase 2 N=62 An Efficacy And Safety Study Of Tanezumab For The Treatment Of Pain Associated With Chronic Abacterial Prostatitis
Chronic Prostatitis With Chronic Pelvic Pain Syndrome
Primary: Change From Baseline in Average Daily Pain Score at Week 6 — 5.5; 5.6; -1.4; -1.0 units on a scale
N/A N=4,412 Healthy Mind Healthy You: A Study of Mindfulness
Stress
Primary: Estimated Weekly Change on World Health Organization-5 (WHO-5) — 0.78; 0.76; 0.41; 0.33 estimated weekly change in scale score — p=.820
Phase 3 N=280 A Study for Patients Who Completed VITALITY-ALS (CY 4031)
Amyotrophic Lateral Sclerosis (ALS)
Primary: Number of Participants With Adverse Events — 112; 157 Participants
Phase 4 N=77 Wirelessly Observed Therapy in Comparison to Directly Observed Therapy for the Treatment of Tuberculosis
Tuberculosis
Primary: Step 1: Positive Detection Accuracy (PDA) — 99.3 percentage of DHFS detected doses
N/A N=45 Transcranial Magnetic Stimulation (TMS) for Motor Symptoms in Psychiatric Disorders
Psychomotor Retardation · Psychomotor Slowing · Schizophrenia and Related Disorders
Primary: Number of Responders at Week 3 — 4; 9; 0; 3 responders